RG-101: Phase I started

Regulus began an open-label, U.S. Phase I trial to evaluate 2 mg/kg subcutaneous RG-101 in 8 healthy volunteers, 8 patients with severe renal impairment or end-stage renal disease (ESRD) and 8 HCV-inf...